Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
Bindia Jharap(Meander Medisch Centrum), Jean‐Frédéric Colombel(Mount Sinai Hospital), Geert D’Haens(Amsterdam University Medical Centers), B Huang(AbbVie (United States)), W. Wang(AbbVie (United States)), Roopal Thakkar(Abbott (United Kingdom)), A. Lazar(AbbVie (Germany)), Walter Reinisch(Medical University of Vienna), A. M. Robinson(AbbVie (United States)), William J. Sandborn(University of San Diego)
Cited by 82
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k